Spectral AI (NASDAQ:MDAI – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11), Zacks reports.
Here are the key takeaways from Spectral AI’s conference call:
- Spectral AI said it still expects an FDA response by the end of Q2 2026 for its De Novo application, with a goal of moving quickly toward commercialization of DeepView by the end of 2026.
- The company received $31.7 million in accelerated BARDA funding, which it said supports additional feature development and procurement of up to 30 DeepView devices for burn and trauma settings.
- Q1 revenue was $4.0 million versus $6.7 million a year ago, mainly because the base phase of the BARDA Project BioShield contract wound down. Management said the decline was partly offset by other U.S. government work, including the handheld device program.
- The company highlighted encouraging commercial preparation, including a strong showing at the American Burn Association meeting, expanding international opportunities in the U.K., Australia, and GCC markets, and progress on an outcome study intended to support DeepView’s clinical and economic value.
- Financially, Spectral AI ended the quarter with about $11.7 million in cash, $8.5 million of debt, and reiterated full-year 2026 revenue guidance of approximately $18.5 million, excluding meaningful DeepView product sales.
Spectral AI Stock Performance
NASDAQ MDAI traded down $0.18 during trading on Tuesday, hitting $2.15. The stock had a trading volume of 790,425 shares, compared to its average volume of 596,340. Spectral AI has a 12 month low of $1.18 and a 12 month high of $3.21. The company’s 50-day moving average price is $1.67 and its two-hundred day moving average price is $1.65. The company has a market capitalization of $68.41 million, a PE ratio of -6.94 and a beta of 1.16.
Institutional Inflows and Outflows
Analysts Set New Price Targets
MDAI has been the topic of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $3.00 target price on shares of Spectral AI in a report on Wednesday, March 25th. Weiss Ratings lowered shares of Spectral AI from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Spectral AI currently has a consensus rating of “Hold” and a consensus price target of $3.00.
View Our Latest Stock Report on Spectral AI
Spectral AI Company Profile
Spectral AI, Inc (NASDAQ: MDAI) is a technology company focused on delivering advanced analytics and insights through the application of machine learning to multi-spectral and hyperspectral data. Its core platform ingests imagery from satellites, aerial drones and ground-based sensors, applying proprietary algorithms to identify patterns and anomalies invisible to the naked eye. The company’s solutions are designed to help clients make more informed decisions in areas such as agriculture, environmental monitoring, infrastructure inspection and resource exploration.
The company offers a cloud-native software-as-a-service (SaaS) platform that enables users to visualize and analyze large volumes of spectral data via customizable dashboards.
Featured Stories
- Five stocks we like better than Spectral AI
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.
